C-Peptide-Positive, Autoantibody-Negative Type 1 Diabetes Mellitus

Area of Science:

• Endocrinology
• Immunology
• Metabolic Disorders

Background:

• Type 1 diabetes mellitus (T1DM) is often characterized by the autoimmune destruction of pancreatic beta cells, leading to insulin deficiency.
• Current clinical trial inclusion criteria for T1DM immunotherapies frequently assume complete and irreversible loss of beta cell function, particularly in patients diagnosed longer than a specified period.
• This assumption may exclude individuals with residual or potentially regenerating beta cell function, limiting therapeutic research.

Observation:

• A 30-year-old female with a history of C-peptide (CP)-positive, autoantibody-negative T1DM presented with evolving glycemic control.
• Initial diagnosis at age 19 showed low-normal CP (1 ng/mL) and negative GAD-65 antibodies.
• Nearly a decade later, at age 28, repeat testing revealed normal CP levels (2.1 ng/mL) alongside elevated GAD-65 antibodies (38.2 U/mL), confirming T1DM.

Findings:

• The observed increase in CP levels suggests potential pancreatic beta cell regeneration or enhanced function over time.
• This finding contradicts the prevailing belief of rapid and complete beta cell function loss in all T1DM patients.
• Measurable CP levels correlate with reduced rates of diabetic complications, indicating a potential protective role.

Implications:

• Residual C-peptide production in T1DM may signify preserved beta cell capacity, challenging current diagnostic and therapeutic trial criteria.
• Further research into CP's role in T1DM is warranted to explore its influence on inflammation, microvascular/endothelial function, and potential neuro-glomerular protection.
• Understanding CP dynamics could lead to more inclusive clinical trial designs and novel therapeutic strategies for T1DM management.